Antiretroviral Pregnancy Registry (APR)-Risk of Birth Defects
This study is currently recruiting participants.
Verified October 2017 by ViiV Healthcare
First Posted: June 7, 2010
Last Update Posted: October 24, 2017
Information provided by (Responsible Party):
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study is currently recruiting participants.|
|Estimated Study Completion Date:||December 31, 2024|
|Estimated Primary Completion Date:||December 31, 2024 (Final data collection date for primary outcome measure)|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Vannappagari V, Albano JD, Koram N, Tilson H, Scheuerle AE, Napier MD. Prenatal exposure to zidovudine and risk for ventricular septal defects and congenital heart defects: data from the Antiretroviral Pregnancy Registry. Eur J Obstet Gynecol Reprod Biol. 2016 Feb;197:6-10. doi: 10.1016/j.ejogrb.2015.11.015. Epub 2015 Nov 24.
Vannappagari V, Koram N, Albano J, Tilson H, Gee C. Association between in utero zidovudine exposure and nondefect adverse birth outcomes: analysis of prospectively collected data from the Antiretroviral Pregnancy Registry. BJOG. 2016 May;123(6):910-6. doi: 10.1111/1471-0528.13542. Epub 2015 Aug 12.